Brief: Inozyme Announces Acceptance Of First European Clinical Trial Application For Phase 1/2 Clinical Trial Of Inz-701 In Abcc6 Deficiency

Inozyme Pharma

09/06/2021 12:36

June 9 (Reuters) - Inozyme Pharma Inc  INZY.O :
    * INOZYME ANNOUNCES ACCEPTANCE OF FIRST EUROPEAN CLINICAL
TRIAL
APPLICATION FOR PHASE 1/2 CLINICAL TRIAL OF INZ-701 IN ABCC6
DEFICIENCY
    * INOZYME PHARMA INC - CLINICAL TRIAL INITIATION EXPECTED IN
MID-2021
    * INOZYME PHARMA INC - PRELIMINARY SAFETY AND BIOMARKER DATA
EXPECTED BY END OF 2021

Source text for Eikon:  ID:nGNX4N5q7 
Further company coverage:  INZY.O 

 ((Reuters.Briefs@thomsonreuters.com;))